Impact of Acute and Chronic Inflammation on Cytochromes P450 Activity Measured With Dried Blood Spot

NCT ID: NCT03262051

Last Updated: 2021-03-04

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 106 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-09-01
• Study Completion Date: 2021-09-01

Brief Summary

Cytochromes P450, main enzymes of drug metabolism, play a prominent role in the first-pass metabolism of oral substances. Inter-individual variability in their activity due to genetic and environmental factors has been observed and may be associated with adverse therapeutic outcomes (ineffectiveness or toxicity). The inflammation, whether acute or chronic, can theoretically modulate the pharmacokinetics of drugs by modulating enzyme activity. Indeed, in vitro data and animal models, as well as more limited data in humans, indicate a down-regulation of CYP in the context of inflammation.

The cocktail approach developed and validated in Geneva ("cocktail Geneva") measures the activity of several CYP simultaneously using micro-doses of probe drugs and facilitating sampling (10uL capillary blood) on a dried blood spot.

We intend to measure the activity of CYP in an acute inflammation model (hip surgery and SARS-CoV-2 infection) and chronic inflammation (rheumatoid arthritis, RA). The effect of the biological agent tocilizumab (anti IL-6 receptor) in a treated patient subgroup (patients treated regardless of our study) will be measured after 3 months of treatment.

The main objective is to determine if interleukin 6 levels are correlated with the activity of CYP450 in patients with acute (orthopedic surgery - hip or SARS-CoV-2 infection) or chronic inflammation (RA).

Secondary objectives are:

• To correlate CYPs activities with the levels of other inflammatory markers (CRP, TNF-α, IL-1β, IFN-γ);
• To assess correlation between markers of inflammation, CYP activities and the intensity of fatigue and pain;
• To assess if tocilizumab reverse CYP activity in patients with RA after 3 months treatment;
• To assess if SARS-CoV-2 infection modify pharmacokinetic parameters of concomitant medications which are CYPs substrates

Conditions

Inflammation

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Patient with acute inflammation (surgery)

patients undergoing hip surgery

CYP phenotyping

Intervention Type: DIAGNOSTIC_TEST

Phenotyping using a simplified version of the Geneva cocktail

Patient with chronic inflammation

patients with rheumatoid arthritis

CYP phenotyping

Intervention Type: DIAGNOSTIC_TEST

Phenotyping using a simplified version of the Geneva cocktail

Patient with acute inflammation (SARS-CoV-2 infection)

patients with SARS-CoV-2 infection

CYP phenotyping

Intervention Type: DIAGNOSTIC_TEST

Phenotyping using a simplified version of the Geneva cocktail

Interventions

CYP phenotyping

Phenotyping using a simplified version of the Geneva cocktail

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Male and female patients diagnosed with rheumatoid arthritis or undergoing an elective hip surgery
• Age > 18 years old
• Understanding of French language and ability to give a written inform consent

For SARS-CoV-2 infection group

• Male and female patients diagnosed with SARS-CoV-2 infection (positive RT-PCR) and CRP > 30 mg/L
• Age > 18 years old
• Understanding of French language and ability to give a written inform consent

Exclusion Criteria

• Pregnant or lactating females
• Severe cardiac failure, severe edema or ascites
• Severe COPD or pulmonary embolism requiring oxygen
• Uncontrolled infection
• Active cancer
• HIV infection
• Renal impairment (defined as serum creatinine concentrations > 1.5 x ULN)
• Hepatic impairment (alteration of hepatic tests AST, ALT, bilirubin, GGT >2 x ULN)
• Inability to give blood samples
• Sensitivity to any of the drugs used
• Intake of drugs altering CYPs activity (based on [1]) except for tocilizumab

For SARS-CoV-2 infection group

• Pregnant or lactating females
• Hospitalized in intensive care unit at time of inclusion
• Hospitalized in intermediate care unit at time of inclusion
• Active cancer
• HIV infection
• Renal impairment (glomerular filtration rate < 30 mL/min/1.73m2)
• Hepatic impairment (Child-Pugh score B and C)
• Inability to give blood samples
• Sensitivity to any of the drugs used

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Geneva

OTHER

Sponsor Role: lead

Responsible Party

Caroline Samer

Doctor, University Hospital, Geneva

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Geneva University Hospitals, HUG

Geneva, , Switzerland

Site Status: RECRUITING

Countries

Switzerland

Central Contacts

Caroline Samer, MD

Role: CONTACT

caroline.samer@hcuge.ch

+41 22 382 99 47

Facility Contacts

Caroline Samer

Role: primary

Other Identifiers

2016-02232

Identifier Type: -

Identifier Source: org_study_id